RM
Ricardo Miranda
Structural biology: designs the order of disulfide bond formation.
LinkedInToday you compensate with cold chain, encapsulation, or overdosing — patches that add cost to every batch. We re-engineer the order in which disulfide bonds form so the protein withstands your real process, without relying on those workarounds.
Your enzymes and biomolecules perform well in the lab assay. The problem shows up in the real process: heat, contact time, and storage deactivate them before they finish their job. Today this gets solved outside the molecule: cold chain, encapsulation, enteric coating, or simply overdosing to compensate for what's lost along the way.
By the time it reaches the hot step of the process, the enzyme has already lost useful activity.
We compensate with a higher dose or a lower temperature, and that raises cost or slows down everything else.
If it isn't refrigerated properly in transit, it expires before we can even use it.
Expensive logistics and stock breaks, just to sustain a molecule that can't hold up on its own.
We encapsulate and overdose to hide the fact that the protein can't take the process.
Every patch adds cost and a new variable that can fail in production, in every batch.
Every workaround you sustain carries a recurring cost: more dose, more logistics, more failure points. The question worth asking isn't how to hide the protein's fragility better — it's why keep paying to hide it, when it can be solved in the molecule's design.
We work on the root of the problem, not its symptoms: we re-engineer the order in which a protein's disulfide bonds form so structural stability replaces the workaround.
We start from a proprietary library of modules derived from snake, spider, and scorpion venoms — naturally ultra-stable — to propose variants before touching the lab.
The core of the platform: we don't add disulfide bonds at random — we control the order in which they form during folding. That order is what determines whether a protein ends up ultra-stable or not.
We simulate folding before synthesis to rule out weak candidates and cut down trial-and-error cycles in the wet lab.
We validate in the lab the variants that performed best in simulation, with the expression team connected to IBt-UNAM.
We measure stability under your process's real conditions — temperature, contact time, pH — not just the standard lab assay.
We design a scoped pilot with you around your enzyme or protein of interest, with success criteria defined before starting.
Disulfide-bond design for protein stabilization is an active research field, not an idea exclusive to Cys-BioTech. These are public materials, in case you want to see the scientific grounding before scheduling a call.
Cys-BioTech spun out of this institute; the science team remains connected to Dr. Gerardo Corzo's lab.
ibt.unam.mx →Peer-reviewed study on how designing extended disulfide bonds increases a protein's structural stability.
pnas.org →Academic review of disulfide-bond engineering strategies for improving the stability of industrial and therapeutic proteins.
febs.onlinelibrary.wiley.com →Cys-BioTech is part of GRIDX's (GRID Exponential) IGNITE program, which connects LatAm biotech with investors.
gridexponential.com →Sources: ibt.unam.mx · Enhancing protein stability with extended disulfide bonds, PNAS, 2016 (DOI 10.1073/pnas.1605363113) · Protein disulfide engineering, FEBS Letters, 2014 (DOI 10.1016/j.febslet.2013.11.024) · gridexponential.com.
We agree on the process condition the protein must withstand (temperature, contact time) before designing.
You'll receive the test results, with the method used, so your own technical team can evaluate them.
If the variant meets the target, you have a real technical basis to reduce cold chain, encapsulation, or overdosing.
We define upfront what it means for the pilot to have worked, so there's no ambiguity when evaluating it.
We document the in silico design and validation process, so you can audit where every result comes from.
At the end of the pilot, we decide together whether to scale up, adjust the design, or set this technical path aside.
Uses an industrial enzyme or protein that loses activity from heat, time, or storage.
Today pays the cost of a workaround: cold chain, encapsulation, or overdosing.
Has an in-house technical team that can evaluate stability data and define a success criterion.
Can sustain a scoped pilot, without yet committing to a production volume.
Understands we're at validation stage, not buying a product already on the market.
If your process today depends on a workaround to sustain a fragile protein, a technical conversation is worth having.
Tell us which vertical you work in (industrial laundry, animal nutrition, cosmeceuticals, food and beverage, or other) and which process condition you need to withstand.
Tell us your vertical and process condition, and we'll set up a short technical conversation.
We use your data only to respond to you. No spam.
We received your message. We'll reach out to schedule the call.